Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maher Albitar

Showing results (41-50 of 214) with videos related to

Pageof 22
Sort By:
Cancer|February 6, 2009
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Leukemia Research|March 7, 2003
Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatmentApostolia Maria Tsimberidou, Tracey Waddelow, Hagop M Kantarjian, et al.
Leukemia Research|October 19, 2010
Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevanceWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Leukemia Research|October 12, 2004
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assayIman Jilani, Michael Keating, Francis J Giles, et al.
Acta Haematologica|April 1, 2009
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitorsWanlong Ma, Hagop Kantarjian, Chen-Hsiung Yeh, et al.
Leukemia & Lymphoma|October 11, 2007
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometryJoanne Bareng, Iman Jilani, Mercedes Gorre, et al.
Cancer|September 5, 2002
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemiaRaymond Lai, Susan O'Brien, Taghi Maushouri, et al.
Plos One|August 23, 2011
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modelingTai-Sung Lee, Hagop Kantarjian, Wanlong Ma, et al.
Cancer|March 15, 2008
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulationsTai-Sung Lee, Steven J Potts, Hagop Kantarjian, et al.
Journal of Clinical Pathology|October 3, 2018
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignanciesCory Batenchuk, Maher Albitar, Kim Zerba, et al.
Pageof 22

Showing results (41-50 of 214) with videos related to

Sort By:
Pageof 22
Cancer|February 6, 2009
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulationsTai-Sung Lee, Wanlong Ma, Xi Zhang, et al.
Leukemia Research|March 7, 2003
Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatmentApostolia Maria Tsimberidou, Tracey Waddelow, Hagop M Kantarjian, et al.
Leukemia Research|October 19, 2010
Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevanceWanlong Ma, Hagop Kantarjian, Xi Zhang, et al.
Leukemia Research|October 12, 2004
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assayIman Jilani, Michael Keating, Francis J Giles, et al.
Acta Haematologica|April 1, 2009
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitorsWanlong Ma, Hagop Kantarjian, Chen-Hsiung Yeh, et al.
Leukemia & Lymphoma|October 11, 2007
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometryJoanne Bareng, Iman Jilani, Mercedes Gorre, et al.
Cancer|September 5, 2002
Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemiaRaymond Lai, Susan O'Brien, Taghi Maushouri, et al.
Plos One|August 23, 2011
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modelingTai-Sung Lee, Hagop Kantarjian, Wanlong Ma, et al.
Cancer|March 15, 2008
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulationsTai-Sung Lee, Steven J Potts, Hagop Kantarjian, et al.
Journal of Clinical Pathology|October 3, 2018
A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignanciesCory Batenchuk, Maher Albitar, Kim Zerba, et al.
Pageof 22